How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

542 results for

Famciclovir

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

361. A Double-Blind Randomized Clinical Trial Comparing the Safety and Antiviral Activity of 48-week Clevudine and Adefovir Dipivoxil in HBeAg(-) Chronic Hepatitis B With Compensated Liver Function

positive with DNA levels ≥ 1 x 10(5) copies/mL within 30 days of baseline. Patient has ALT levels which are in the range of 2 x ULN and < 10 X ULN Patient who has not a history of ascites, variceal hemorrhage or hepatic encephalopathy. Exclusion Criteria Patient is currently receiving antiviral or corticosteroid therapy. Patients previously treated with lamivudine, adefovir, entecavir, telbivudine, clevudine, lobucavir, famciclovir or any other investigational nucleoside for HBV infection. Previous

2008 Clinical Trials

362. Prednisolone Priming Study in Patients With Chronic Hepatitis B

acyclovir or famciclovir (e.g., for recurrent herpes virus infections). History of hepatocellular carcinoma (HCC) or findings suggestive of possible HCC, such as suspicious foci on imaging studies or elevated serum alpha-fetoprotein (AFP) levels. A history of treated malignancy other than HCC is allowable if the patient's malignancy has been in complete remission, off chemotherapy and without additional surgical intervention, during the preceding 3 years. One or more known primary or secondary causes

2008 Clinical Trials

363. Scandinavian Bell's Palsy Study

women not employing acceptable methods of contraception and/or women planning to become pregnant during the period with intake of study medication. Subjects with a history of immunodeficiency syndromes. Subjects with an allergy or sensitivity to aciclovir or valaciclovir, famciclovir or ganciclovir. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information

2007 Clinical Trials

364. Effect of HSV-2 Suppressive Therapy on Sexual Behavior

with the study protocol Exclusion Criteria: Pregnancy or intention to become pregnant within the next year Suppressive therapy with acyclovir, valacyclovir, or famciclovir within 2 weeks of enrollment/randomization 6 or more symptomatic herpes recurrences in the prior 12 months or in the 12 months prior to starting suppressive therapy if on suppressive therapy during the prior 12 months HIV seropositive or known immunocompromising medical condition. HIV negative test must be performed within 60 days of Visit

2007 Clinical Trials

365. HSV-2 Suppression to Reduce HIV-1 Levels in HIV-1 Co-infected Persons

-confirmed asymptomatic gonorrhea and syphilis) are treated within two weeks of study enrollment and random assignment. Exclusion Criteria: Women who meet any of the following criteria are not eligible for this study: Known history of adverse reaction to valacyclovir, acyclovir or famciclovir; Planned open label use of acyclovir, valacyclovir, or famciclovir Known medical history of seizures Known renal failure, serum creatinine >2.0mg/dl Hematocrit < 30 % Contacts and Locations Go to Information from

2007 Clinical Trials

366. Iontophoretic Application of Acyclovir Gel to Treat Cold Sores

-1 isolates know to be resistant to acyclovir, valacyclovir, famciclovir, or ganciclovir. Subject has had a herpes vaccine. Subject is currently enrolled in another clinical trial involving the use of a drug and/or a device. Subject has previously participated in the current study (TPI-H-221). Subject requires chronic use of analgesics, pain medication or non-steroidal anti-inflammatory agents (NSAIDs). Subject has a recent history of renal dysfunction or serious hepatic disease. Subject has

2007 Clinical Trials

367. Trial to Study the Effect of Dose of Herpes Simplex Virus-2 (HSV-2) Suppressive Therapy on HSV and HIV

clinical evaluations Willing and able to take study drug as directed Willing and able to adhere to follow-up schedule Exclusion Criteria: Known history of adverse reaction to acyclovir, valacyclovir, or famciclovir Planned open label use of acyclovir, valacyclovir, or famciclovir History of evidence of CMV disease Known medical history of seizures Known renal insufficiency, defined as serum creatinine greater than 1.5 mg/dl AST or ALT greater than 3 times upper limit of normal Hematocrit less than 30

2007 Clinical Trials

368. Patient-initiated Episodic Treatment of Recurrent Genital Herpes in Black Patients

: Novartis Information provided by: Novartis Study Details Study Description Go to Brief Summary: This study will evaluate the safety and efficacy of single-day famciclovir episodic treatment in Black patients with recurrent genital herpes Condition or disease Intervention/treatment Phase Genital Herpes Drug: Famciclovir Drug: Placebo Phase 4 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 463 participants Allocation: Randomized (...) Intervention Model: Parallel Assignment Masking: Double (Participant, Investigator) Primary Purpose: Treatment Official Title: A Randomized, Multicenter, Double-blind Study to Compare the Efficacy of Single-day Treatment (1000 mg b.i.d.) With Famciclovir Compared to That of Placebo in Patient-initiated Episodic Treatment of Recurrent Genital Herpes in Immunocompetent Black Patients Study Start Date : June 2007 Actual Primary Completion Date : March 2009 Actual Study Completion Date : March 2009 Resource

2007 Clinical Trials

369. Adefovir Dipivoxil Tablets (10mg) In Chinese Subjects With HBe Antigen Negative Chronic Hepatitis B

or thymosin), systemic cytotoxic agents, chronic anti-viral agents excluding lamivudine (e.g. ganciclovir, adefovir dipivoxil, entecavir, famciclovir, FTC, DAPD, LFMAU, HBIg), Chinese herbal medicines known to have activity against HBV within the previous 12 months or during the study; use of agents with effect of ALT reduction (e.g. schisandra agents) during the study Use of lamivudine within the previous 3 months or during the study Planned for liver transplantation or previous liver transplantation

2006 Clinical Trials

370. Safety and Antiviral Activity Study of Clevudine 30 Mg QD in Patient With Chronic HBV

with lamivudine, lobucavir, famciclovir, adefovir or any other investigational nucleoside for HBV infection. Previous treatment with interferon that had ended less than 6 months prior to the screening visit. Patients with a history of ascites, variceal hemorrhage or hepatic encephalopathy. Patients co-infected with HCV, HDV or HIV. Patients with clinical evidence of liver mass or with alpha-fetoprotein > 50 ng/mL Patients who were pregnant or breast-feeding. Patients who were unwilling to use an "effective

2006 Clinical Trials

371. Safety and Antiviral Activity Study of Clevudine 30 Mg QD in Patients With HBeAg(-) Chronic HBV

therapy. Patients previously treated with lamivudine, lobucavir, famciclovir, adefovir or any other investigational nucleoside for HBV infection. Previous treatment with interferon that had ended less than 6 months prior to the screening visit. Patients with a history of ascites, variceal hemorrhage or hepatic encephalopathy. Patients coinfected with HCV, HDV or HIV. Patients with clinical evidence of liver mass or with alfa-fetoprotein > 50 ng/mL Patients who were pregnant or breast-feeding. Patients

2006 Clinical Trials

372. Safety and Efficacy Study of L-FMAU in Chronic HBV Patients of L-FMAU-201 Placebo Group

)experienced a >= 1 log10 decrease from baseline in HBV DNA at Week 48 Exclusion Criteria: Patient with HBeAg seroconverted to anti-HBe at the last 2 consecutive visits (one month apart) in L-FMAU-201 study. Patient who was currently receiving antiviral, immunomodulatory or corticosteroid therapy. Patient who was treated with lamivudine, lobucavir, famciclovir, adefovir or any other investigational nucleoside for HBV infection after cessation of treatment in L-FMAU-201 study. Patient who had a history

2006 Clinical Trials

373. Valacyclovir+Temovate Gel for the Treatment of Herpes Labialis

study has been proposed because it has become clear there are marked limitations to the benefit of antiviral therapy in herpes labialis. Recently, a pilot trial of the combination of famciclovir and topical 0.05% fluocinonide vs famciclovir alone showed that the addition of corticosteroids to the antiviral drug treatment caused a marked and statistically significant reduction in lesion size and a trend to more aborted lesions. This study is designed as a randomized, placebo-controlled, , patient

2006 Clinical Trials

374. Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection

[TDF], emtricitabine (FTC), clevudine, telbivudine [LdT], famciclovir), or any other experimental anti-HBV antiviral agent Therapy with interferon, thymosin alpha or other immunostimulators within 24 weeks of enrollment (i.e., dosing) into this study Subjects who require chronic administration of concomitant medications which cause immunosuppression or which are associated with a high rate of nephrotoxicity or hepatotoxicity, or which affect renal excretion, should not be enrolled in this study

2006 Clinical Trials

375. VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2

treatments (e.g., valacyclovir, acyclovir, ganciclovir, famciclovir) within 3 days of starting study drug, or immunomodulatory treatments in the 30 days before starting study drug. Subject has clinically significantly impaired renal function as defined by creatinine clearance less than 50ml/min (calculated using the Cockcroft-Gault formula). Subjects with a history or evidence of decompensated liver disease, or clinically significantly impaired hepatic function defined as an ALT (alanine transaminase (...) ) level >3 times the normal upper limit. Subject is known to be hypersensitive to valacyclovir, acyclovir, ganciclovir or famciclovir. Subject has malabsorption or vomiting syndrome or other gastrointestinal dysfunction that may impair drug pharmacokinetics. Female subject who is contemplating pregnancy within the duration of the study drug dosing period. Female subject who is pregnant and/or nursing. Subject with current alcohol or drug abuse. Subjects who have received suppressive (daily) therapy

2006 Clinical Trials

376. Study Comparing the Safety of Switching From Lamivudine to Adefovir Dipivoxil Versus Overlapping Lamivudine and Adefovir Before Adefovir Dipivoxil Monotherapy in Patients With Chronic Hepatitis B

demonstrating potential anti-HBV activity other than lamivudine within the previous 3 months (e.g. famciclovir, lobucavir, emtricitabine, DAPD, L-FMAU, entecavir, ganciclovir or others). History of hypersensitivity to nucleoside and/or nucleotide analogues. Clinical, ultrasonographic or radiologic evidence of hepatic mass suggestive of hepatocellular carcinoma. Serum alphafetoprotein (AFP) > 50 ng/mL at the first screening visit. However, if the AFP level is > 50 ng/mL at the first screening visit, but has

2006 Clinical Trials

377. Adefovir Dipivoxil For The Treatment Of Chinese Compensated Chronic Hepatitis B(CHB)Patients

by the investigator to be sufficient to hinder compliance with treatment, participation in the study or interpretation of results. Use of immunosuppressive therapy, immunomodulatory therapy (including interferon or thymosin), systemic cytotoxic agents within the previous 6 months or during the study. Use of chronic anti-viral agents(e.g. lamivudine, adefovir dipivoxil, entecavir, famciclovir, tenofovir, FTC, ganciclovir, DAPD, LfMA, HBIg, etc.), Chinese herbal medicines known to have activity against HBV within

2007 Clinical Trials

378. Efficacy and Safety of Telbivudine in Treatment naïve Patients With Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB)

in the 12 months before Screening for this study. Has a medical condition that required prolonged or frequent use of systemic acyclovir or famciclovir. Has a medical condition that requires frequent or prolonged use of systemic corticosteroids although inhaled or intra-articular corticosteroids are allowed. Has a medical condition requiring the chronic or prolonged use of potentially hepatotoxic drugs or nephrotoxic drugs. Is currently abusing alcohol or illicit drugs or has a history of alcohol abuse

2006 Clinical Trials

379. Usage of Acyclovir for Suppression of HIV-1 and HSV-2 Coinfected Persons in Cameroon

criteria are not eligible for this study. Known history of adverse reaction to acyclovir Planned open label use of acyclovir, valacyclovir, or famciclovir Positive pregnancy test Active opportunistic infection Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number

2005 Clinical Trials

380. Valganciclovir to Treat HHV-8 Associated Multicentric Castleman's Disease

protocol. For HIV-infected participants, a stable antiretroviral regimen for the past 6 months Exclusion Criteria: Concurrent Kaposi sarcoma or non-hodgkin's lymphoma A history or evidence of CMV disease Hypersensitivity to ganciclovir or valganciclovir Use of high-dose acyclovir (>800 mg bid), valacyclovir (>1000 mg qd) or famciclovir (>1000 mg qd), ganciclovir, foscarnet, or cidofovir Neutropenia (ANC <1500) Renal insufficiency with serum creatinine > 1.5 mg/ml or CrCl < 60 AST or ALT > 5 times upper

2006 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>